Background: Immune modulating nutrition (IMN) has been shown to reduce complications after major surgery, but strong evidence to recommend its routine use is still lacking. Objective: The aim of this meta-analysis was to evaluate the impact of IMN combinations on postoperative infectious and noninfectious complications, length of hospital stay, and mortality in patients undergoing major open gastrointestinal surgery. Methods: Randomized controlled trials published between January 1980 and February 2011 comparing isocaloric and isonitrogenous enteral IMN combinations with standard diet in patients undergoing major open gastrointestinal surgery were included. The quality of evidence and strength of recommendation for each postoperative outcome were assessed using the GRADE approach and the outcome measures were analyzed with RevMan 5.1 software (Cochrane Collaboration, Copenhagen, Denmark). Results: Twenty-six randomized controlled trials enrolling 2496 patients (1252 IMN and 1244 control) were included. The meta-analysis suggests strong evidence in support of decrease in the incidence of postoperative infectious [risk ratio (RR) (95% confidence interval [CI]): 0.64 (0.55, 0.74)] and length of hospital stay [mean difference (95% CI): −1.88 (−2.91, −0.84 days)] in those receiving IMN. Even though significant benefit was observed for noninfectious complications [RR (95% CI): 0.82 (0.71, 0.95)], the quality of evidence was low. There was no statistically significant benefit on mortality [RR (95% CI): 0.83 (0.49, 1.41)]. Conclusions: IMN is beneficial in reducing postoperative infectious and noninfectious complications and shortening hospital stay in patients undergoing major open gastrointestinal surgery. (Ann Surg 2012;255:1060-1068) E arly initiation of enteral nutrition after major abdominal surgery has been shown to decrease postoperative complications and length of hospital stay. 1 Supplementation of enteral feeds with im-From the
mune modulators such as L-arginine, L-glutamine, ω-3 fatty acids, and nucleotides is thought to modify immune and inflammatory responses favorably and result in reduced postoperative infective complications. [2] [3] [4] [5] [6] [7] Although immune modulating nutrition (IMN) has been investigated in critical illness, surgery, sepsis, trauma, and burns, its precise role in the management of these conditions is not clearly established because of conflicting clinical outcomes. [8] [9] [10] [11] Reasons for the inconsistent results are not clear but could reside in the differences in the clinical, nutritional, and metabolic status of these patients. Moreover, the study population in the earlier randomized controlled trials (RCTs) and meta-analyses on IMN included widely heterogeneous patients (eg, critical illness and elective surgery), making direct comparisons difficult. 2, [12] [13] [14] [15] [16] Animal and human studies have demonstrated beneficial effects of individual components of IMN in modifying immune and inflammatory responses. Furthermore, combinations of 2 or more IMN have been shown to enhance host defenses to a significantly greater extent than when used alone. 4, [17] [18] [19] Currently available metaanalyses 6, 7 of IMN in surgical patients have included RCTs supplementing both single and multiple IMN in the experimental group, making the treatment effect of either of them difficult to interpret. Moreover, since the publication of the most recent meta-analysis of RCTs up to September 2009, 7 additional studies using IMN on surgical patients and guidance for rating the quality of evidence and strength of recommendations using the "Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system" have been published. 20, 21 Therefore, we performed this meta-analysis to determine the effect of combinations of 2 or more IMN components against isocaloric, isonitrogenous standard enteral diet on postoperative clinical outcomes utilizing the GRADE approach in a relatively homogenous group of patients undergoing elective major open gastrointestinal surgery. diet with similar timing of initiation, dose, and duration in both the experimental and control groups provided for minimum of 5 days (pre-, post-, or perioperatively) in adult patients undergoing major elective open abdominal surgery were included in the analysis. If an RCT had a complex study design with more than 2 arms, only data of relevant study groups were included for analysis.
RCTs providing single IMN in the study group, no supplementation in the control group and the studies in which desired outcome were not measured; non-randomized designs, case-controlled trials, retrospective studies, and other studies that did not fulfill the inclusion criteria were excluded. Any RCT comparing pre-or postoperative IMN supplementation with perioperative IMN supplementation or in any combinations were also excluded.
Data Collection and Analysis
Two authors (K.M. and K.K.V.) examined the publications independently and extracted data according to predefined criteria. RCTs were assessed for the methodology, study design, inclusion and exclusion criteria, and outcome measures. The methodological quality of each RCT was recorded for method of randomization, blinding, protocol violation, and allocation concealment and scored using the JADAD scale. 22 Any disagreement was resolved by consensus discussions with the other members of the review team (D.N.L. and O.L.). Data collected included age, nutritional status, type and composition of study and control enteral diet, timing, dose and duration of supplementation, route of feeding, nutritional target to be achieved, and other additional measures taken to prevent or reduce infection.
Clinical outcomes were recorded according to intention-totreat analysis where available and included postoperative infectious and noninfectious complications, length of hospital stay, and mortality. Infectious complications included general, wound-related, and organ-specific infections as described in the studies.
Statistical Analysis
Outcome measures included in this meta-analysis, using the standard methods recommended by the Cochrane Collaboration, 23 were (1) postoperative infectious complications, (2) postoperative noninfectious complications, (3) length of hospital stay, and (4) mortality. We report effect sizes for dichotomous outcomes as risk ratio (RR) with 95% confidence intervals (CIs) and continuous outcomes as mean differences (MD). Pooled analyses were performed using the fixed-effects model with the Mantel-Haenszel method or randomeffects model with the inverse variance method. Statistical heterogeneity was assessed by the I 2 statistic and threshold values of I 2 equal to 25%, 50%, and 75%, represent low, moderate, and high heterogeneity, respectively. These analyses were performed using RevMan 5.10 software (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark).
The quality of the evidence for each outcome was comprehensively assessed and graded using GRADEpro software, 24 as recommended by the Cochrane Collaboration. The judgments of the quality of specific outcome were based on 5 main domains: limitations of the study design and execution, inconsistency, indirectness, imprecision of results, and publication bias across all studies that measured each outcome. The overall quality of the evidence for each outcome is the result of a combination of the systematic assessments in all domains and is graded as very low, low, moderate, or high to make a recommendation for intervention or alternate management.
RESULTS

Eligible Studies
Twenty-six RCTs published between January 1992 and September 2010 fulfilled the inclusion criteria, leading to a total of 2496 patients (24-303/study), 1252 in IMN group, and 1244 in control group ( Fig. 1 and Table 1 ). Appropriate randomization methods (randomization number table or computer generated) were reported in 14 studies. 25, 26, 30, 33, 35, 36, 38, 39, 41, 43, 44, [46] [47] [48] Allocation concealment was documented in 14 studies 25, 26, 30, 33, 35, 36, [38] [39] [40] [41] 43, 44, [46] [47] [48] using either sealed envelope or allocating through an external member. Twelve of the RCTs were described as double blind 25, 26, 30, [32] [33] [34] [35] [36] 38, 39, 41, 44, 47, 48 but the blinding methodology was explained in only 5. 30, 33, 35, 38, 41 A minimum follow-up of 30 days was documented in 6 studies. 26, 30, 33, 36, 41, 48 Protocol violation after randomization was reported in 18 studies. 25, 27, [30] [31] [32] [33] [34] [35] [36] [38] [39] [40] [41] [43] [44] [45] 47, 48 Only 18 RCTs had a JADAD score of 3 or more. 25, 26, [29] [30] [31] [32] [33] [34] [35] [36] [38] [39] [40] [41] 43, 44, 47, 48 Standard criteria for inclusion and exclusion were defined in all the studies but length of hospital stay, wound complications, and organ specific-and general complications were defined in 15 studies. 27, 30, 31, 33, 34, [36] [37] [38] [39] [41] [42] [43] [44] 46, 48 These complications were defined using different criteria between studies.
Patient Characteristics
All studies included patients with and without weight loss except one RCT, 48 which included only malnourished patients with 10% weight loss or BMI of less than 18 kg/m 2 . Preoperative nutritional status was based on history of weight loss in the previous 6 months in 12 studies 25, 26, [29] [30] [31] [32] 34, 38, 40, 43, 44, 51 and compared against ideal body weight in 7 studies. 27, 33, 36, 41, 45, 47, 49 Mean age of the patients in the IMN group was 61.9 (0.76) and in the control group was 62.5 (0.81). postoperative, and perioperative nutritional support with IMN were considered together as 1 group, even if they were divided into 2 or 3 separate groups for comparison in the original publication. IMPACT (Novartis, Bern, Switzerland) was used in 18 studies. STRESSON (Nutricia Ltd, Zoetermeer, The Netherlands), RECONVAN (Fresenius Kabi, Bad Homburg, Germany), and ALITRA Q (Ross Laboratories, Columbus, OH) were used in 4, 2, and 1 studies, respectively ( Table 2 ). All preparations contained ω-3 fatty acids and arginine. IMPACT did not contain glutamine but was the only preparation to contain nucleotides. The other preparations contained glutamine. IMN was given preoperatively for 5 to 7 days in 6 studies 28, 32, 36, 42, 45, 46 and postoperatively for a minimum of 5 days in 15 studies [25] [26] [27] [29] [30] [31] [37] [38] [39] 41, 43, 44, [47] [48] [49] and perioperatively in 3 studies. 33, 34, 50 Postoperative supplementation was started 6 to 36 hours after surgery and continued for 5 to 7 days or until patients resumed their oral intake to maintain 60% of their daily calorie requirement. Perioperative supplementation was commenced 5 days before surgery in 1 study 33 and 7 days before in 2 studies, 34, 50 and this was continued postoperatively for at least 7 days in 1 study 33 and 5 days in another. 34 Isocaloric and isonitrogenous enteral diet was used as a control diet in all the studies and in 4 studies the control diet had some amount of key IMN. [37] [38] [39] 41 Enteral feeds were administered through nasoenteral 27, 35, 39, 40, 42, 43 or per-oral 28, 32, 36, 45, 46, 50 route in 12 studies and through feeding jejunostomy in 10 studies. 25, 26, 30, 34, 38, 41, 44, [47] [48] [49] Depending on type and nature of surgery, feeding jejunostomy or nasoenteral feeding tubes were used within the same study group in 4 studies. 29, 31, 33, 37 Target dosage for preoperative supplementation was 1000 mL/d in 2 studies. 33, 34 Dosage of enteral nutrition and time taken to reach postoperative nutritional goals varied between studies. Target calories for postoperative supplementation were either calculated as kcal/kg/d in 11 studies [27] [28] [29] 31, [37] [38] [39] 42, 45, 49 (25 to 30 kcal/kg or based on the Harris Benedict equation) or given as fixed volume, 1 to 1.5 L/day in 4 33, 34, 36, 46 or 60 to 100 mL/h in 8. 25, 26, 30, 34, 41, 43, 44, 48 Twelve studies aimed to achieve target calorie requirement within the third to fifth postoperative day. 25, 26, 30, 31, 33, 34, 37, 38, 41, 43, 44, 48 
Analysis of Postoperative Outcomes
Postoperative outcomes were analyzed in 26 studies that included a total of 2496 patients. Subgroup analyses were also performed on the basis of the timing of initiation of the diet (Table 3) . In this analysis, 20 of the included studies have defined the outcome variables [25] [26] [27] [29] [30] [31] 33, 34, [36] [37] [38] [39] [41] [42] [43] [44] [46] [47] [48] [49] but only 5 of them assessed the outcome with same definitions. In addition, 30-day follow-up after surgery was only available for 6 studies. 26, 30, 33, 36, 41, 48 
Infectious Complications
Postoperative infectious complications were reported in 2496 patients (IMN: 1252; Control: 1244) from 26 studies. IMN resulted in a 36% reduction in postoperative infectious complications when compared with standard enteral nutrition (Fig. 2) .
Noninfectious Complications
Twenty studies with total of 1941 patients (IMN: 973 and Control: 968) compared noninfectious complications between IMN and control group. Patients who received IMN had 18% fewer noninfectious complications (Fig. 3 ).
Length of Hospital Stay
Mean length of hospital stay with standard deviation was presented in 20 studies with a total of 2097 patients (IMN: 1052; Control: 1045), and in 3 studies it was presented as median with range or interquartile range (hence, not included). Patients who received IMN had a significantly shorter hospital stay than those who received standard enteral nutrition (Fig. 4 ).
Postoperative Mortality
Postoperative mortality was documented in 25 studies, which included 2378 patients and was similar in both groups (Fig. 5 ).
DISCUSSION
In this meta-analysis of 26 RCTs evaluating the impact of IMN in patients undergoing elective major open gastrointestinal surgery, significant reductions in postoperative infectious and noninfectious complications and shortened hospital stay were observed when compared with an isocaloric and isonitrogenous "standard" feed. Furthermore, on subgroup analysis based on timing of initiation, significant reduction in the incidence of infectious complications was demonstrated after pre-, post-and perioperative supplementation (Fig. 2) . However, significant beneficial effects of IMN on noninfectious complications and length of hospital study were noted only in patients receiving peri-and postoperative nutrition. There was no difference in postoperative mortality when comparisons were made between individual groups or subgroups.
Although, previous meta-analyses 6, 7 have demonstrated the benefits of IMN in surgical patients, on closer examination there are some potential methodological issues. A recent meta-analysis 7 included studies that provided supplementation initiated at different time periods in control and experimental groups 36, 51 or no supplementation in the control group. 52, 53 Moreover, the control groups in 3 of the included studies 36, 51, 52 were counted twice when pooling the results, which could create a "unit-of-analysis error." In RCTs 10, 42, [52] [53] [54] that compare IMN in the experimental group with no supplementation 55, 56 in the control group, the observed treatment effects could be simply due to improvement in the overall nutritional status owing to provision of extra calories. Moreover, comparison of pre-or postoperative IMN against perioperative IMN supplementation or in any combinations primarily evaluates the impact of timing of initiation of IMN in relation to surgery rather than the effectiveness of IMN supplementation over standard diet. In addition, these comparisons could also lead to inconsistency and imprecision in methodology between the studies during meta-analysis. Previous meta-analyses 2, 3, 9, 57 have included patients with burns, trauma, and critical illness together with patients undergoing major surgery and these heterogeneous comparisons could mask the actual benefits of IMN in surgical patients.
Having addressed the previously described issues, in an attempt to improve the methodological quality and strength of evidence, this meta-analysis was performed using RCTs that compared experimental IMN against an isocaloric and isonitrogenous standard diet with similar timing of initiation, dose, and duration on patients who underwent elective major open gastrointestinal surgery. RCTs that primarily evaluated the impact of timing of IMN supplementation 51, 52, 58, 59 or subgroup analysis of the much larger clinical trials 58, 60 were excluded. GRADEpro analysis, which uses an "outcome-centric approach" to grade the quality of evidence and strength of Varying inclusion criteria based on nutritional status of patients. 2 Studies fulfilling less than 3 elements for risk of bias are considered to have limitations in design. 3 Underreporting of noninfectious complications. 4 Discrepancy in the definition of length of hospital stay. 5 30-day postoperative follow-up was not available in some studies. 6 No explanation was provided.
recommendations, showed an acceptable overall methodological quality of this meta-analysis and also demonstrated a low likelihood of publication bias, which increase the confidence in the internal validity of our findings ( Table 4 ). The strength of evidence based on GRADEpro for the critical outcomes (infectious complications and length of hospital stay) was moderate, which concurs with the statistically significant benefit in the IMN group. We have downgraded the quality of evidence for noninfectious complications because of selective reporting of this outcome in majority of the studies. However, some of the confounding factors present in the individual studies should be taken into context. Most of the included RCTs studied both malnourished and well-nourished patients, but some studies have included only malnourished patients 48 or excluded obese patients. 27 This could result in a potential bias as it has been clearly established that perioperative nutrition may be beneficial in moderately to severely malnourished patients, and in contrast routine use of nutritional support in all the patients undergoing major surgery have not shown an improvement in clinical outcomes when either morbidity or mortality is used as an endpoint. 61 Similarly, if IMN was assumed to be more effective on malnourished patients, overall study outcome would be dependant on numbers of malnourished patients included in the study.
Another potential source of bias could be assessment of outcome variables using varying definition criteria between the RCTs. In this analysis, only 6 studies (mostly from the same group) assessed the outcome with same definitions. In addition, 30-day follow-up after surgery was available for only 7 studies. Nonavailability of the 30-day follow-up data could have significant impact on the overall study outcome as it misses out the incidence of delayed infectious and noninfectious complications and postoperative mortality.
Evidence suggests that at least 5 to 7 days of supplementation of IMN is needed to maximize the benefit 62 and, therefore, preoperative supplementation of IMN is expected to result in more pronounced benefits in patients undergoing major surgical procedures as the opportunity exists to enrich the IMN content in the body before the induction of surgical trauma. Moreover, during the postoperative period, enteral nutrition is usually commenced in small amounts through nasoenteral route or feeding jejunostomy and it takes a few days to achieve full dosage. In addition, significant numbers of patients develop complications related to enteral feed or route of administration, which preclude them to have a sufficient amount of IMN during immediate postoperative period. On the contrary, preoperative supplementation did not show significant advantage over perioperative or postoperative IMN supplementation in this meta-analysis. One of the possible explanations could be a small sample size from the 3 available RCTs supplementing preoperative IMN, which results in lower quality of evidence and imprecise estimate of the treatment effect for preoperative IMN. Interestingly earlier studies most often provided IMN postoperatively and this may be in part due to the logistic difficulty and/or costs associated with starting preoperative support.
The concentrations of IMN present in the body fluids may be critical in determining the degree of response to surgical trauma. In RCTs using postoperative IMN supplementation, the dosage was based on body weight or total daily energy requirement but the target dose in this group was achieved only on the fourth or fifth postoperative day in most studies (Table 1 ). In contrast, preoperative supplementation was given as a fixed volume and was not based on the patient's body weight. Although substantial amounts of IMN must be present in the body for clinically beneficial response, supraphysiological amounts of IMN, especially arginine, can be detrimental to patients. Two well-designed RCTs investigating a role of IMN in the trauma patients but differing in amount of arginine (6.6 g/L compared with 14 g/L) in the supplement had shown a detrimental outcome when arginine levels were substantially high. 63, 64 It has also been increasingly recognized that potential benefit or harm from IMN is dependent on metabolic and immunological state of the patient at the time of IMN supplementation. For instance, septic patients showed worse outcome when supplemented with arginine-based IMN. 8, 12 This observed difference in the outcome could be related to altered metabolism of arginine during septic conditions. These observations suggest that an optimal therapeutic range exists for the beneficial effects of IMN, which needs to be established.
CONCLUSIONS
In summary, this meta-analysis of RCTs supplementing IMN in patients undergoing major elective abdominal surgery suggests significant reduction in postoperative complications and length of hospital stay when compared with standard enteral nutrition. This relative improvement in the postoperative clinical outcome was more pronounced when IMN was given peri-or postoperatively. This analysis, using GRADEpro approach, has also provided a summary of the issues relating to methodology and quality of studies evaluating IMN supplementation in surgical patients. Robustly designed RCTs are still needed to evaluate the benefits of preoperative over postoperative supplementation and well nourished over malnourished patients. It also became evident that methodological differences among clinical trials hamper comparisons of study outcomes. There are also some specific areas such as molecular signaling pathways where gaps in the knowledge still exist. Future research could take a more focused approach to identify specific mechanisms by which IMN improves the host defense in humans and to determine the optimal dose of IMN to promote these mechanisms.
